ClinicalTrials.gg
RecruitingNCT07007143STAR-TEER ⅡUpdated Mar 9, 2026

STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant

A Phase 4 interventional study of Experimental: Aspirin monotherapy and Active Comparator: Aspirin+Clopidogrel in Mitral Regurgitation, sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,032
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Mitral Valve Insufficiency with a site in China — 44 open to participants now, 46 under way, none of them phase 3. Mitral Valve Insufficiency · China.

Planned enrollment
Largest of 40
1,032 · median 127
Started
2025
with 8 others
Phase 4
4 of 57
3 open now
Primary completion
2028-09
later than 36 of 45 live
Registered
40th of 57
by date
Lead sponsor
2 of 57
Chinese Academy of Medical Sciences, Fuwai Hospital

Among the 57 studies in Mitral Valve Insufficiency with a site in China, this one has the largest planned enrollment of the 40 interventional ones that give a count, is one of 9 that started in 2025, is one of 4 in phase 4, reaches primary completion later than 36 of the 45 other live ones, and was the 40th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

44 of the 57 studies in Mitral Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Mitral Valve Insufficiency with a site in China, or all of them as a file.
02

Study summary

Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups). Transcatheter edge-to-edge repair (TEER) is now a well-established strategy in high-risk patients with MR. Globally, over 250,000 patients have benefited from the TEER technique. However, no dedicated study has prospectively evaluated different antithrombotic strategies following TEER in patients undergone TEER procedure. Current guidelines do not provide any recommendations for the antithrombotic management of TEER. Consequently, considerable treatment variation exists in clinical studies and practice. The investigators will conduct a multicenter, open-label randomized trial to compare different antithrombotic strategies following TEER in patients without an indication for OAC.

03

Conditions studied

  • Mitral Regurgitation

Keywords

  • Transcatheter Edge-to-Edge Repair (TEER)
  • Mitral Regurgitation
  • Cardiovascular Diseases
  • Embolism and Thrombosis
  • Bleeding
  • Aspirin
  • Clopidogrel
  • Antithrombotic treatment
  • Platelet Aggregation Inhibitors
  • Antiplatelet Drug
  • Single Antiplatelet Therapy(SAPT)
  • Double Antiplatelet Therapy(DAPT)
  • Stroke
  • Myocardial Infarction
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Successful TEER procedure, defined as technical success per MVARC criteria.
  • Ability and willingness to comply with the trial protocol.
  • Provision of written .
  • Women of must use effective from the time of consent until the final dose of antithrombotic therapy.
  • Antithrombotic strategy approved by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Severe renal impairment ( \< 15 mL/min or requiring dialysis).
  • Ongoing postoperative bleeding (defined as overt bleeding with a ≥3.0 g/dL drop in or requiring ≥3 units of blood transfusion), or vascular complications following the index TEER procedure.
  • count \< 50 × 10\^9 /L.
  • Need for reoperation due to complications of the index TEER procedure.
  • Recent ( \< 12 month) intracranial or intracerebral hemorrhage.
  • Recent ( \< 12 month) gastrointestinal ulcers or hemorrhage.
  • Hepatic disease with coagulopathy.(eg, class B or C cirrhosis).
  • Allergy, intolerance, or to research drugs.
  • Participation in another drug or device study within 30 days.
  • Indication for long-term OAC.
  • Absolute indication for dual antiplatelet therapy; (eg, recent PCI).
  • \< 12 months.
  • Pregnancy or breastfeeding.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,032 participants (estimated)

Study arms

  • Experimental
    Aspirin monotherapy

    Participants will receive Aspirin monotherapy (100 mg once daily, minimum 12 months).

    Drug: Experimental: Aspirin monotherapy

  • Active comparator
    Aspirin + Clopicogrel

    Participants will receive Aspirin (100 mg once daily, minimum 12 months) plus clopidogrel (75 mg once daily for 3 months).

    Drug: Active Comparator: Aspirin+Clopidogrel

Interventions

06

What researchers measure

Primary outcomes

  1. All bleeding complications at 1 year after TEER

    For the classification of bleeding complications, the Mitral Valve Academic Research Consortium (MVARC) Primary Bleeding Scale is used. All bleeding can be categorized into five types: minor bleeding, major bleeding, extensive bleeding, life-threatening bleeding, and fatal bleeding.

    Time frame: 1 year

Secondary outcomes

  1. Non-procedure-related bleeding complications at 1 year after TEER(key secondary outcome 1)

    Non-procedure-related bleeding is consisted of all MVARC bleeding, excluding Bleeding Academic Research Consortium (BARC ) type 4 severe bleeding.BARC type 4 severe bleeding is defined by any of the following: perioperative intracranial bleeding within 48 hours, reoperation after closure of sternotomy for the purpose of controlling bleeding, transfusion of 5 or more units of whole blood or packed red cells within a 48-hour period, chest-tube output of 2 or more liters within a 24-hour period.

    Time frame: 1 year

  2. Composite of ischemic event (1)(key secondary outcome 2)

    composite of all-cause mortality, stroke, systemic embolic events , or myocardial infarction at 1 year after TEER

    Time frame: 1 year

  3. Composite of ischemic event (2)

    Composite of cardiovascular mortality, ischemic stroke, systemic embolic events ,or myocardial infarction at 1 year after TEER.

    Time frame: 1 year

  4. Composite of ischemic and bleeding events(1)

    Composite of all bleeding, all-cause mortality, stroke, systemic embolic events or myocardial infarction at 1 year after TEER.

    Time frame: 1 year

  5. Composite of ischemic and bleeding events(2)

    Composite of non-procedure-related bleeding events, cardiovascular mortality, ischemic stroke, systemic embolic events or myocardial infarction at 1 year after TEER.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wang C, Liu Z, Li Z, Yan X, Wang C, Zhou N, Zhang F, Ouyang W, Zhao G, Ma J, Wang S, Pan X. STrategies for antithrombotic tRreatment following transcatheter edge-to-edge repair in patients with severe mitral regurgitation: Rationale and design of STAR-TEER trial. Am Heart J. 2026 Jun;296:107362. doi: 10.1016/j.ahj.2026.107362. Epub 2026 Jan 28. PubMed 41616808 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Sep 2028, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2025
First posted
Jun 5, 2025
StartActual
Jul 31, 2025
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2029
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07007143
Responsible party
Pan Xiangbin (Principal Investigator, Chinese Academy of Medical Sciences, Fuwai Hospital) — Principal investigator
First posted
Jun 5, 2025
Start date
Jul 31, 2025
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Mar 9, 2026

Study contacts

Xiangbin Pan, MD,PhD
Contact
panxiangbin@fuwaihospital.org
+86(10)88396666
Zizheng Liu, M.B
Contact
liuzizheng00@126.com
+86(10)88396666
Xiangbin Pan, MD,PhD
principal investigator · Chinese Academy of Medical Sciences, Fuwai Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion